



Wegovy® Prior Authorization Request Form (Page 1 of 2)

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)			Provider Information (required)		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:		Specialty:
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:
Medication Information (required)					
Medication Name:			Strength:		Dosage Form:
☐ Check if requesting brand			Directions for Use:		
☐ Check if request is for continuation of therapy					
Clinical Information (required)					
Select the diagnosis below:					
☐ Reduce the risk of major adverse cardiovascular event (MACE) without diabetes					
☐ Noncirrhotic metabolic dysfunction-associated steatohepatitis without diabetes					
☐ Other diagnosis: _____ ICD-10 Code(s): _____					
Not covered for obesity or weight management or Type 2 diabetes mellitus					
Clinical information:					
List the patient's HbA1c _____ within the last 2 months					
List the patient's BMI to one decimal place (i.e., 25.1, 36.8, etc) _____					
For major adverse cardiovascular event without diabetes:					
1. Patient has established cardiovascular disease as evidenced by one of the following:					
a. Prior myocardial infarction ☐ Yes ☐ No List ICD-10 code(s) _____					
b. Prior stroke ☐ Yes ☐ No List ICD-10 codes _____					
c. Peripheral arterial disease ☐ Yes ☐ No List ICD-10 codes _____					
2. Is the patient taking lipid-lowering and antiplatelet therapy? List drugs _____					
3. Is the member a current tobacco user? ☐ Yes ☐ No					
a. If yes, did the member receive tobacco cessation counseling? ☐ Yes ☐ No					
For noncirrhotic metabolic dysfunction-associated steatohepatitis without diabetes:					
1. Is the patient's fibrosis stage F2 or F3? ☐ Yes ☐ No					
2. Prescriber attests patient is participating in a supervised weight management plan that encourages behavioral modification, reduced calorie diet, and increased physical activity. ☐ Yes ☐ No					
3. Does the patient have decompensated cirrhosis (Child-Pugh Class B or C)? ☐ Yes ☐ No					
4. Select if the requested medication is prescribed by or in consultation with one of the following specialists:					
☐ Endocrinologist ☐ Gastroenterologist ☐ Hepatologist ☐ Other _____					
5. Will the medication be co-administered with another GLP-1 receptor agonist (e.g., Saxenda, Trulicity, Victoza, etc)? ☐ Yes ☐ No					
If the request is for Wegovy tablets:					
Has the member had a 90-day trial and failure of Rybelsus tablet? ☐ Yes ☐ No					

This document and others if attached contain information that is privileged, confidential and/or may contain protected health information (PHI). The Provider named above is required to safeguard PHI by applicable law. The information in this document is for the sole use of OptumRx. Proper consent to disclose PHI between these parties has been obtained. If you received this document by mistake, please know that sharing, copying, distributing or using information in this document is against the law. **If you are not the intended recipient, please notify the sender immediately.**

Office use only: Wegovy_SouthDakotaMedicaid_2026April



Wegovy® Prior Authorization Request Form (Page 2 of 2)

Quantity limit requests:

What is the quantity requested per MONTH? _____

What is the reason for exceeding the plan limitations?

- ☐ Titration or loading dose purposes
- ☐ Patient is on a dose-alternating schedule (e.g., one tablet in the morning and two tablets at night, one to two tablets at bedtime)
- ☐ Requested strength/dose is not commercially available
- ☐ Other: _____

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note:

This request may be denied unless all required information is received.
For urgent or expedited requests please call 1-855-401-4262.
This form may be used for non-urgent requests and faxed to 1-844-403-1029.